Cargando…

Successive immunosuppressive treatment of fulminant myocarditis that is refractory to mechanical circulatory support

BACKGROUND: Long-term prognosis in patients with fulminant myocarditis can be favorable; however, for 32–36% of patients, this condition becomes fatal during the acute stages despite the use of mechanical circulatory support. Other therapeutic options may be needed for patients in whom these conditi...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakashima, Hiroshi, Umeyama, Yasuhiro, Minami, Kazutoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3700499/
https://www.ncbi.nlm.nih.gov/pubmed/23826449
http://dx.doi.org/10.12659/AJCR.889109
_version_ 1782275518866915328
author Nakashima, Hiroshi
Umeyama, Yasuhiro
Minami, Kazutoshi
author_facet Nakashima, Hiroshi
Umeyama, Yasuhiro
Minami, Kazutoshi
author_sort Nakashima, Hiroshi
collection PubMed
description BACKGROUND: Long-term prognosis in patients with fulminant myocarditis can be favorable; however, for 32–36% of patients, this condition becomes fatal during the acute stages despite the use of mechanical circulatory support. Other therapeutic options may be needed for patients in whom these conditions are resistant to aggressive management. CASE REPORT: We present a case of fulminant myocarditis that rapidly progressed to cardiogenic shock and in-hospital cardiac arrest in a 46-year-old male. The patient promptly received inotropic agents, intra-aortic balloon pump therapy, and extracorporeal membrane oxygenation. However, creatinine kinase (CK), C-reactive protein (CRP), and QRS width increased significantly between days 1 and 3 of treatment; the patient’s hemodynamic profile deteriorated despite this treatment regimen. Intravenous methylprednisolone was initiated on day 3 at a dose of 1,000 mg/day and maintained for an additional three days. Less than 24 h after methylprednisolone administration, the QRS width decreased significantly from 0.44 s to 0.18 s. In addition, CK and CRP levels declined sharply, which is associated with hemodynamic improvement. CONCLUSIONS: High doses of intravenous methylprednisolone may be considered a therapeutic option for patients with fulminant myocarditis that is refractory to usual management practices.
format Online
Article
Text
id pubmed-3700499
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-37004992013-07-03 Successive immunosuppressive treatment of fulminant myocarditis that is refractory to mechanical circulatory support Nakashima, Hiroshi Umeyama, Yasuhiro Minami, Kazutoshi Am J Case Rep Case Report BACKGROUND: Long-term prognosis in patients with fulminant myocarditis can be favorable; however, for 32–36% of patients, this condition becomes fatal during the acute stages despite the use of mechanical circulatory support. Other therapeutic options may be needed for patients in whom these conditions are resistant to aggressive management. CASE REPORT: We present a case of fulminant myocarditis that rapidly progressed to cardiogenic shock and in-hospital cardiac arrest in a 46-year-old male. The patient promptly received inotropic agents, intra-aortic balloon pump therapy, and extracorporeal membrane oxygenation. However, creatinine kinase (CK), C-reactive protein (CRP), and QRS width increased significantly between days 1 and 3 of treatment; the patient’s hemodynamic profile deteriorated despite this treatment regimen. Intravenous methylprednisolone was initiated on day 3 at a dose of 1,000 mg/day and maintained for an additional three days. Less than 24 h after methylprednisolone administration, the QRS width decreased significantly from 0.44 s to 0.18 s. In addition, CK and CRP levels declined sharply, which is associated with hemodynamic improvement. CONCLUSIONS: High doses of intravenous methylprednisolone may be considered a therapeutic option for patients with fulminant myocarditis that is refractory to usual management practices. International Scientific Literature, Inc. 2013-04-23 /pmc/articles/PMC3700499/ /pubmed/23826449 http://dx.doi.org/10.12659/AJCR.889109 Text en © Am J Case Rep, 2013 This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License
spellingShingle Case Report
Nakashima, Hiroshi
Umeyama, Yasuhiro
Minami, Kazutoshi
Successive immunosuppressive treatment of fulminant myocarditis that is refractory to mechanical circulatory support
title Successive immunosuppressive treatment of fulminant myocarditis that is refractory to mechanical circulatory support
title_full Successive immunosuppressive treatment of fulminant myocarditis that is refractory to mechanical circulatory support
title_fullStr Successive immunosuppressive treatment of fulminant myocarditis that is refractory to mechanical circulatory support
title_full_unstemmed Successive immunosuppressive treatment of fulminant myocarditis that is refractory to mechanical circulatory support
title_short Successive immunosuppressive treatment of fulminant myocarditis that is refractory to mechanical circulatory support
title_sort successive immunosuppressive treatment of fulminant myocarditis that is refractory to mechanical circulatory support
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3700499/
https://www.ncbi.nlm.nih.gov/pubmed/23826449
http://dx.doi.org/10.12659/AJCR.889109
work_keys_str_mv AT nakashimahiroshi successiveimmunosuppressivetreatmentoffulminantmyocarditisthatisrefractorytomechanicalcirculatorysupport
AT umeyamayasuhiro successiveimmunosuppressivetreatmentoffulminantmyocarditisthatisrefractorytomechanicalcirculatorysupport
AT minamikazutoshi successiveimmunosuppressivetreatmentoffulminantmyocarditisthatisrefractorytomechanicalcirculatorysupport